GlaxoSmithKline (GB:GSK) has released an update.
GlaxoSmithKline’s RSV vaccine, Arexvy, has received European Commission approval for use in adults aged 50-59 at increased risk of respiratory syncytial virus (RSV) disease. This demographic, estimated at 20 million in Europe, can now be immunized against RSV ahead of the upcoming season, building on prior approvals for those 60 and over. The vaccine’s expansion is supported by positive phase III trial results and aims to alleviate health and healthcare system burdens caused by RSV.
For further insights into GB:GSK stock, check out TipRanks’ Stock Analysis page.
